Investigational pharmacological treatments for Parkinson’s disease

Handbook of Parkinson's Disease, Third Edition

Volumn , Issue , 2003, Pages 453-461

  Ondo, William ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34249945382     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (25)

1. Konitsiotis S, Oh JD, Metman LV. Continuous transdermal dopaminergic stimulation in advanced Parkinson’s disease. Adv Neurol 2001; 86:355-360.
2. Metman LV, Gillespie M, Farmer C, Bibbiani F, Konitsiotis S, Morris M, et al. Continuous transdermal dopaminergic stimulation in advanced Parkinson’s disease. Clin Neuropharmacol 2001; 24:163-169.
3. Hutton JT, Metman LV, Chase TN, Juncos JL, Koller WC, Pahwa R, et al. Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson’s disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov Disord 2001; 16:459-463.
4. Bianchine J, Poole K, Woltering F. Efficacy and dose response of the novel transdermally applied dopamine agonist rotigotine CDS in early Parkinson’s disease. Neurology 2002; 58(suppl 3):A162-A163.
5. Svensonn K, Carlsson A, Huff R, Kling P, Waters N. Behavioural and neurochemical data suggests functional differences between dopamine D2 and D3 receptors. Eur J Pharmacol 1994; 263:235-243.
6. Veinberg A, Lerner D, Goldenberg W, Levy R, Youdim M, Finberg J, et al. Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat. J Neural Transm Suppl 1998; 52:301-305.
7. Katzir O, Rehavi M, Zabarski T, Cohen S, Huang W. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Pharmacol Biochem Behav 1998; 60:387-393.
8. Kirschbaum-Slager N, Lazarovici P, Bejar C, Youdim MB, Shoham S, Maruyama W. Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. NY Acad Sci 2001; 939:148-161.
9. Akao Y, Youdim MB, Davis BA, Naoi M, Rabey JM. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson’s disease: a double-blind study as adjunctive therapy to levodopa. J Neurochem 2001; 78:727-735.
10. Parkinson Study Group. A controlled trial of early Parkinson’s disease. Ann Neurol 2000; 48(suppl):489.
11. Parkinson Study Group. Earlier treatments with rasagiline may attenuate (UPDRS) progression of PD. Mov Disord 2001; 16:981.
12. Parkinson Study Group. Tyramine challenge to assess the safety of rasagaline monotherapy in a placebo-controlled multicenter trial for early Parkinson’s disease (the TEMPO study). Neurology 2001; 56(suppl 3):A345.
13. Shellenberger M, Clarke A, Donoghue S. Zydis selegiline reduces time and improves symptoms in patients with Parkinson’s disease. Mov Disord 2001; 15(suppl 2):116-117.
14. Daly J, Butts-Lamb P, Padgett W. Subclass of adenosine receptors in the central nervous system: interaction with caffeine and related methylxanthines. Cell Mol Neurobiol 1983; 8:69-74.
15. Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, et al. Adenosine A2A receptors modify motor function in MPTP-treated common marmosets. Ann Neurol 1998; 43:507-513.
16. Sakamaki T, Kanda T, Ito Y, Sumino H, Masuda H, Ohyama Y, et al. Adenosine A2A receptors modify motor function in MPTP-treated common marmosets. Res Commun Mol Path Pharmacol 1998; 101:25-34.
17. Hubble J, Hauser R. A novel adenosine antagonist (KW-6002) as a treatment for advanced Parkinson’s disease with motor complications. Neurology 2002; 58(suppl 3):A162.
18. Sherzai A, Bara-Jimenez W, Gillespie M, et al. Adenosine Aza antagonist treatment of Parkinson’s disease. Neurology 2002; 58(suppl 3):A467.
19. Harris CA, Deshmukh M, Tsui-Pierchala B, Maroney AC, Johnson EM, Jr., Ylikoski J. Inhibition of the c-Jun N-terminal kinase signaling pathway by the mixed lineage kinase inhibitor CEP-1347 (KT7515) preserves metabolism and growth of trophic factor-deprived neurons. J Neurosci 2002; 22:103-113.
20. Le S, Connors TJ, Maroney AC. c-Jun N-terminal kinase specifically phosphorylates p66ShcA at serine 36 in response to ultraviolet irradiation. J Bio Chem 2001; 276:48332-48336.
21. Maroney AC, Glicksman MA, Basma AN, Walton KM, Knight E, Jr., Murphy CA, et al. Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway. J Neurosci 1998; 18:104-111.
22. Bibbiani F, Oh JD, Chase TN. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001; 57:1829-1834.
23. Nutt J, Brownstein J, Carter J, Comella C. Intraventricular administration of GDNF in the treatment of Parkinson’s disease. Neurology 2001; 56(suppl 3):A375.
24. Gil S, Patel N, O’Sullivan K, Brooks D. Intraparenchymal putaminal administration of glial-derived neurotrophic factor in the treatment of advanced Parkinson’s disease. Neurology 2002; 58(suppl 7):A241.
25. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease. Science 2000; 290:767-773.